Cytosorbents Corp Files 8-K on Financials

Ticker: CTSO · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1175151

Cytosorbents CORP 8-K Filing Summary
FieldDetail
CompanyCytosorbents CORP (CTSO)
Form Type8-K
Filed DateAug 14, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, 8-k

TL;DR

Cytosorbents filed an 8-K detailing their latest financial results.

AI Summary

Cytosorbents Corporation filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition as of August 13, 2024. The filing details financial statements and exhibits related to the company's performance.

Why It Matters

This 8-K filing provides crucial updates on Cytosorbents Corporation's financial health and operational results, which can influence investor decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Cytosorbents Corporation's results of operations and financial condition, along with providing financial statements and exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is August 13, 2024.

What is the filing date of this 8-K report?

This 8-K report was filed on August 14, 2024.

Where are Cytosorbents Corporation's principal executive offices located?

Cytosorbents Corporation's principal executive offices are located at 305 College Road East, Princeton, New Jersey 08540.

What is the Commission File Number for Cytosorbents Corporation?

The Commission File Number for Cytosorbents Corporation is 001-36792.

Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-13 17:40:54

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 13, 2024 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing